- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03756922
A DDI Study of FDL169 and FDL176 in Healthy Subjects
30. januar 2020 opdateret af: Flatley Discovery Lab LLC
A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation
A DDI study to assess the safety, tolerability and pharmacokinetics of both; doses of FDL176 with and without co-administration of FDL169 and doses of FDL169 with and without co-administration of FDL176.
Studieoversigt
Status
Suspenderet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is an open-label, non-randomised study.
Enrolment will be in two parallel and independent parts.
Part 1 will assess the safety, tolerability and pharmacokinetics of single doses of FDL176 with and without co-administration of FDL169.
Part 2 will assess the safety, tolerability and pharmacokinetics of repeated doses of FDL169 with and without co-administration of FDL176.
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
78
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Belfast, Det Forenede Kongerige, BT9 6AD
- Celerion GB Ltd
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 55 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Healthy males or non-pregnant, non-lactating healthy females
- Body mass index of 18.0 to 32.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator
- Must agree to follow the study's contraception requirement
Exclusion Criteria:
- Prior or ongoing medical condition, medical history, physical findings, ECG findings or laboratory abnormality that, in the Investigator's (or delegate's) opinion, could adversely affect the safety of the subject or would place the subject at increased risk.
- History of long QT syndrome and/or QT corrected according to Fridericia's formula (QTcF) interval (>450 msec) or QTcF >450 msec at Screening or Day -1.
- Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active.
- Use of any prescription drugs within 14 days or 5 half-lives (whichever is longer) before the first dose of IMP.
- Use of any non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or 5 half-lives (whichever is longer) before the first dose of IMP.
- Use of any prescription and non-prescription medications that are strong inhibitors or moderate inducers of cytochrome P450 3A, within 14 days or 5-half-lives (whichever is longer) before the first dose of IMP. Use of any prescription and non-prescription medications that are strong inducers of cytochrome P450 3A within 28 days before the first dose of IMP.
- Participation in another clinical trial involving receipt of an IMP within the past 90 days.
- Prior exposure to FDL169 or FDL176
- Alkaline phosphatase, aspartate aminotransferase and/or alanine aminotransferase >1.5 x upper limit of normal (ULN) at screening.
- Serum creatinine or total bilirubin >1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%).
- Abnormal renal function at screening, defined as estimated glomerular filtration rate <60 mL/min using the Modification of Diet in Renal Disease (MDRD) equation.
- History of human immunodeficiency virus (HIV) or positive HIV, hepatitis B or hepatitis C results at screening.
- Positive urinary drugs of abuse screen at Screening or Day -1, or positive alcohol breath test at Screening or Day -1. Consumption of alcohol within 24 h prior to admission.
- Consumption of any food or drink containing grapefruit, or Seville oranges (including marmalade and fruit juices) for 14 days before the first dose of IMP.
- Consumptions or foods containing poppy seeds or involvement in strenuous exercise for 3 days before admission.
- Known hypersensitivity to any component of the formulation of FDL169 or FDL176.
- Pregnant or nursing females.
- History of regular alcohol consumption within 6 months of the study
- Current smoking or use of tobacco products or substitutes.
- Poor peripheral venous access.
- Donation of ≥470 mL blood or loss of blood during surgery or due to trauma within 3 months prior to Day 1.
- Plasma donation within 7 days prior to Day 1.
- Failure to satisfy the Investigator of their fitness to participate for any other reason.
- Site staff, Sponsor staff or first degree family members of site or Sponsor.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Part 1
To receive a single dose of FDL176 on Day 1, followed by FDL169 TID for 28 days starting on Day 29; and another single dose of FDL176 on Day 42.
|
CFTR-korrektor
CFTR potentiator
|
Eksperimentel: Part 2
To receive FDL169 TID for 3 days from Day 1, followed by FDL176 QD for 19 days starting on Day 8; and FDL169 TID for 3 days from Day 24.
|
CFTR-korrektor
CFTR potentiator
|
Eksperimentel: Part 3
FDL169 and FDL176 for 28 days and 4 weeks of follow-up
|
CFTR-korrektor
CFTR potentiator
|
Eksperimentel: Part 4
FDL169 and FDL176 for 28 days and 4 weeks of follow-up
|
CFTR-korrektor
CFTR potentiator
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Pharmacokinetic parameters, Cmax
Tidsramme: Part 1: 14 weeks; Part 2: 12 weeks; Part 3: 12weeks; Part 4: 12 weeks
|
Part 1: the pharmacokinetic parameters of FDL176 when co-administered with FDL169, compared to the pharmacokinetics of FDL176 alone.
Part 2: the pharmacokinetics of FDL169 when co-administered with FDL176, compared to the pharmacokinetics of FDL169 alone.
Part 3: PK when co-administered.
Part 4: Safety and tolerability with multiple dose co-administration in CF subjects
|
Part 1: 14 weeks; Part 2: 12 weeks; Part 3: 12weeks; Part 4: 12 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Tidsramme: Part 1: 14 weeks; Part 2: 12 weeks; Part 3: 12weeks; Part 4: 12 weeks
|
Safety and tolerability when FDL176 and FDL169 are co-administrated,compared to FDL176 alone, and FDL169 alone, as determined by the incidence of adverse events (Aes) and serious adverse events (SAE)s.
Part 4: Combination PK and CF transmembrane conductance regulator activity in CF subjects
|
Part 1: 14 weeks; Part 2: 12 weeks; Part 3: 12weeks; Part 4: 12 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
27. november 2018
Primær færdiggørelse (Forventet)
1. februar 2020
Studieafslutning (Forventet)
1. februar 2020
Datoer for studieregistrering
Først indsendt
27. november 2018
Først indsendt, der opfyldte QC-kriterier
27. november 2018
Først opslået (Faktiske)
28. november 2018
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
5. februar 2020
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
30. januar 2020
Sidst verificeret
1. januar 2020
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- FDL169-2018-10
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med FDL169
-
Flatley Discovery Lab LLCAfsluttetCystisk fibroseDet Forenede Kongerige
-
Flatley Discovery Lab LLCAfsluttetCystisk fibroseDet Forenede Kongerige
-
Flatley Discovery Lab LLCAfsluttetCystisk fibroseDet Forenede Kongerige
-
Flatley Discovery Lab LLCAfsluttetCystisk fibroseDet Forenede Kongerige
-
Flatley Discovery Lab LLCAfsluttetCystisk fibroseDet Forenede Kongerige
-
Flatley Discovery Lab LLCAfsluttetCystisk fibroseDet Forenede Kongerige, Australien, Tyskland, Tjekkiet
-
Flatley Discovery Lab LLCAfsluttetCystisk fibroseDet Forenede Kongerige